http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020526516-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4178 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61D7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12 |
| filingDate | 2018-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2020526516-A |
| titleOfInvention | Angiotensin II receptor blocker for the prevention or treatment of systemic diseases in cats |
| abstract | Disclose a method for preventing or treating hypertension in cats that require treatment for hypertension. The method comprises administering to the cat a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sultan), the therapeutically effective amount of sultan being administered at a daily dose that varies over the duration of treatment. The daily dose of sultan during the first period of treatment is 1.0-5.0 mg / kg (body weight), and the daily dose of this sultan is during the first period of treatment. It will be reduced in the second period that follows. [Selection diagram] None |
| priorityDate | 2017-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 139.